BET-IN-14 is an orally active pan BET inhibitor (IC50: 5.35 nM). BET-IN-14 has anti-cancer activity.
BET-IN-14 (Compound 171) (72 h) shows anti-tumor activity against various cancer cell lines (average IC50: 174.7 nM), especially in MM.1S, Ty-82, MV-4-11, and KG-1 cells[1].
BET-IN-14 (Compound 171) (50 and 100 mg/kg, p.o., qd) inhibits tumor growth in MV-4-11 xenograft[1]。
References:
[1]. Damaneh MS, et al. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. Invest New Drugs. 2020 Jun;38(3):700-713.